Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Jason Levy, MD, FSIR, discusses the clinical considerations, procedural techniques, and ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Jason Levy, MD, FSIR, discusses the clinical considerations, procedural techniques, and ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Heather McArthur speaks about her work examining the impact of preoperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of preoperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
At SIR 2025, VDM spoke with Laura Dawson, MD about the latest literature on SBRT for the treatment of colorectal liver metastases, its real-world clinical applications, and more.
At SIR 2025, VDM spoke with Laura Dawson, MD about the latest literature on SBRT for the treatment of colorectal liver metastases, its real-world clinical applications, and more.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
